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Abstract 
Purpose: To evaluate the efficacy and safety of methotrexate (MTX) nanoparticles in pediatric patients 
with inflammatory bowel disease (IBD). 
Methods: In this randomized, open-label clinical study, 28 pediatric patients with moderate to severe 
IBD were randomly assigned to treatment (MTX nanoparticles,15 mg/week) or control (azathioprine, 
AZA, 2 mg/kg/day) group. Nanoparticles were synthesized by adding calcium chloride to sodium 
alginate solution containing MTX, and was further treated with poly-L-lysine aqueous solution. The 
nanoparticles were evaluated for particle size, zeta potential and drug encapsulation efficacy. 
Erythrocyte sedimentation rate, C-reactive protein, aspartate aminotransferase, alanine transaminase, 
and disease activity scores were used to assess IBD remission.  
Results: Nanoparticle size, zeta potential and encapsulation efficacy were 164.4 ± 6.9 nm, -32.6 ± 3.7 
mV, and 97.8 ± 4.2 %, respectively. After 12 weeks of therapy, the mean Pediatric Crohn's Disease 
Activity Index (PCDAI) scores for control and treatment groups were 22.3 ± 2.14 and 16.8 ± 1.87, 
respectively, while mean Pediatric Ulcerative Colitis Activity (PUCAI) Index scores were 24.3 ± 1.47 and 
18.7 ± 1.92, respectively. Eight patients in the treatment and five patients in the control group achieved 
remission. Biochemical parameters varied significantly between the groups. 
Conclusion: MTX nanoparticles are safe and more effective than standard first-line IBD therapy. 
However, further studies are required to determine the suitability of the formulation for therapeutic use. 
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Inflammatory bowel disease (IBD) is a 
multifactorial disorder characterized by an 
inappropriate immune response that includes 
Crohn’s disease (CD) and ulcerative colitis (UC), 
which are chronic inflammatory intestinal 
idiopathic conditions [1]. IBD may present at any 
age; however, UC and CD occur most frequently 
during the second and third decades of life, 
particularly during adolescence [2,3]. The 
incidence of IBD, CD in particular, has increase 
in recent years [1]. 
 
MTX has been shown to effectively induce and 
maintain remission of CD in adult and pediatric 
patients [2,3], but the effect of MTX on refractory 
IBD was first reported by Kozarek et al [4]. Five 
controlled and several uncontrolled studies have 
demonstrated the effectiveness of MTX in 
inducing remission of steroid-dependent or 
chronic active CD [5-7] and as a steroid-sparing 
agent for the treatment of refractory IBD. 
Furthermore, decreasing the use of steroids may 
reduce the incidence of steroid-related adverse 
effects in patients with chronic IBD. High-dose 
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MTX is associated with several side effects 
including nausea, vomiting, headache, 
abdominal pain, diarrhea, and skin rash. 
 
Nanoparticles are designed to control drug 
release after oral administration, which may 
reduce the dosage frequency as well as the 
incidence of adverse events. Furthermore, 
nanoparticles may protect encapsulated drugs 
from mucosal metabolism, thus increasing 
intracellular drug concentrations [8]. 
 
Alginic acid and sodium and potassium alginates 
are widely used mucoadhesive biomaterials 
because of their good biocompatibility, 
biodegradation [9], sol-gel transition properties, 
and chemical versatility, which allow for further 
modifications [10]. From a regulatory 
perspective, the United States Food and Drug 
Administration (USFDA) considers alginates to 
be “generally recognized as safe” (GRAS), a 
designation that applies to substances accepted 
as safe for alimentary use [11]. GRAS excipients 
are listed in the Code of Federal Regulations 
Title 21 parts 182 and 184 [12]. Thus, because of 
its good biocompatibility, suitability for oral use, 
and USFDA approval, alginate is extensively 
used in the development of nanomedicines. 
 
We evaluated the safety and efficacy of MTX-







MTX was obtained from BBI (Boston, MA, USA). 
Sodium alginate with a molecular weight of 
12,000–40,000 and poly-L-lysine were 
purchased from Sigma–Aldrich (Steinheim, 
Germany). Calcium chloride (CaCl2) and sodium 
chloride (NaCl) were purchased from Merck 
Chemicals [Darmstadt, Germany]. All reagents 
were of analytical grade. 
 
Patient selection and study design 
 
We conducted a randomized, open-label, clinical 
pilot study at Taishan Medical University 
Hospital. The study protocol was approved by 
the local ethics committee of Taishan Medical 
University (approval no. 201367143). Children 
and adolescents between the ages of 8 and 17 
years with moderate to severe IBD were 
recruited. Patients with a Pediatric Ulcerative 
Colitis Activity Index (PUCAI) score >34 or a 
Pediatric Crohn’s Disease Activity Index (PCDAI) 
score >30 were included in the study. Exclusion 
criteria included ileostomy or colostomy, toxic 
megacolon, prior sensitivity or allergy to MTX, 
and having received anti-tumor necrosis factor-α 
(TNF-α) in the previous 8 weeks. Written 
informed consent was obtained from all parents, 
and verbal consent was obtained from all 
participants. The study was conducted according 
to the International Conference on Harmonization 
(ICH) Good Clinical Practices (GCP) and in 
compliance with the Declaration of Helsinki 1975 
[13,14]. 
 
All eligible patients were randomly assigned to 
the treatment (MTX nanoparticles equivalent to 
15 mg/week for 12 weeks) or control (AZA, 2 
mg/kg/day orally for 12 weeks) group. AZA was 
chosen as the comparison treatment because it 
has been widely used as a first-line therapy for 
IBD and is therefore a good standard for this test 
of the efficacy of MTX nanoparticles. All patients 
in the treatment group received a daily folic acid 
supplement. Corticosteroids were used by 64.2 
% of patients in the treatment group and by 71.4 
% in the control group. The steroid dose was 
decreased by 5 mg/week in patients whose 
condition was stable at week 4. All patients were 
restricted from taking immunosuppressants, 
antibiotics, and aminosalicylates during the 
study. 
 
MTX nanoparticle preparation 
 
MTX nanoparticles were synthesized using the 
method reported by Rajaonarivony et al [15]. 
Briefly, 4 mL of 18 mM CaCl2 was added to 76 
mL of 0.06 % sodium alginate solution containing 
MTX while stirring. Then, 16 mL of 0.05 % w/v of 
a poly-L-lysine aqueous solution was added. The 
solution was stirred for 2 h and kept at room 
temperature overnight. Subsequently, the 
solution was centrifuged at 18,000 rpm for 30 
min and washed three times with distilled water 




Particle size  
 
The mean particle size was determined using 
photon correlation spectroscopy (Nanophox 
system, Sympatec GmbH, Clausthal-Zellerfeld, 
Germany). The MTX-loaded nanoparticle 
formulation was diluted with deionized water to a 
pertinent scattering intensity. The data analysis 
was performed using the cumulative method for 
spherical particles. The results were evaluated 
as the effective diameter, and the polydispersity 
index (PDI) was calculated as the relative width 
of the particle size distribution. 
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The zeta potential of the MTX nanoparticle 
formulation was determined using a Nanosight 
NS500 (Malvern Instruments, Ltd., Malvern, UK). 
To obtain the zeta potential, the MTX 
nanoparticle sample was diluted in double-
distilled water and placed in an electrophoretic 
cell. 
 
Fourier transform infrared spectroscopy 
(FTIR) 
 
The FTIR transmission spectra were determined 
using a FTIR-8400S spectrophotometer 
(Shimadzu, Kyoto, Japan). The sample for 
analysis was prepared by mixing pure drug and 
nanoparticle samples with potassium bromide 
powder (1 % of the potassium bromide amount). 
A potassium bromide disc was prepared using 
hydraulic compression at 10,000 psi. The 
potassium bromide disc was scanned over 
wavelength regions of 400–4000 cm-1. 
 
Drug encapsulation efficiency 
 
The drug encapsulation efficiency of the 
nanoparticle formulation was obtained by 
separation of MTX nanoparticles from the 
aqueous medium holding free MTX. The 
formulation was first placed into the dialysis bag 
(Spectra/Por® 3,500 MWCO, Spectrum Medical 
Industries, Los Angeles, CA, USA), which 
allowed dialysis of the free drug until the 
encapsulated drug was complete released. 
During dialysis, the medium, 0.9 % NaCl, was 
changed every 30 min, to monitor the amount of 
free drug. The formulation was considered 
separated when free drug could no longer be 
detected. Triton X 100 (0.1 mL) was added to 2 
mL of the sample solution, which produced a 
clear solution. The encapsulation efficiency (E %) 
of the MTX nanoparticles was measured by 
ultraviolet spectrophotometer (UV-2600, 
Shimadzu) at 303 nm and calculated as in 
Equation 1, 
 
E (%) = ([Da – Db]/Da)100 ………………… (1) 
 
where Da and Db are the drug concentrations 
after and before dialysis, respectively. 
 
In vitro release studies 
 
In vitro drug release from the MTX nanoparticles 
formulation was achieved by dialysis in a 
phosphate-buffered saline solution at pH 7.4. 
The optimized MTX nanoparticles (equivalent to 
2.5 mg of the drug) were placed in a dialysis bag 
and kept in 50 mL of dissolute on a medium; they 
were then placed in shaker incubator that was 
persistently rotated at 100 rpm at 37 °C.  
 
A small amount of solution was withdrawn for the 
analysis. The amount of MTX released from the 
nanoparticles was determined 
spectrophotometrically at 303 nm. Each 
experimental procedure was performed three 
times. The cumulative release of MTX at each 
time point was calculated as the ratio of drug 
released at any time (t) to the initial amount of 
encapsulated drug; that value is expressed as a 
percentage. 
 
Measurement of therapeutic efficacy 
 
Our primary outcome was the feasibility and 
safety of administering MTX nanoparticles to 
children as assessed by the number and severity 
of adverse reactions. The secondary outcome 
was the efficacy of MTX nanoparticles on 
disease activity. A positive clinical response was 
defined as a 10-point decrease from baseline in 
the PCDAI or PUCAI score, with scores < 10 
considered to indicate inactive disease or 
complete remission.  
 
Patients were withdrawn from the study in cases 
of severe infection, persistent thrombocytopenia 
or leukopenia, imminent surgery, unacceptable 
adverse reaction, deterioration of disease 
symptoms, noncompliance, or on the patient’s 
request.  
 
Patients follow up 
 
Patients were followed up at 2, 4, 8, and 12 
weeks during treatment and every 4 weeks for 6 
consecutive months after the trial. At each follow-
up visit, the PCDAI and PUCAI scores were 
evaluated and the patients underwent a complete 
blood count, hemoglobin, C-reactive protein 
(CRP), aspartate aminotransferase (AST), 
alanine transaminase (ALT), and erythrocyte 
sedimentation rate (ESR) tests. 
 
Statistical analysis  
 
All pre- and post-treatment data were assessed 
using Student's paired t-test. All data are 
expressed as means ± standard error (SE). P-
values < 0.05 were deemed to indicate statistical 
significance. All categorical variables were 
assessed using the Chi-square test. Adverse 
events were reported quantitatively and 
qualitatively using the Common Terminology 
Criteria for Adverse Events (CTCAE). The 
Statistical Package for the Social Sciences 
version 9 (SPSS, Inc., Chicago, IL, USA) was 
used to conduct the statistical tests. 
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Patient clinical characteristics 
 
The baseline characteristics of patients in each 
study arm are shown in Table 1. Of 33 patients 
screened for the study, 5 were excluded because 
of prior history of colostomy (n = 1), exposure to 
infliximab (n = 1) and mild disease (n = 3). Thus, 
28 patients (17 males and 11 females) were 
enrolled in the study, and 14 patients were 
randomly assigned to each arm of the study. A 
total of 21 patients had CD and 7 had UC. The 
mean age of participants at the time of enrolment 
was 13.15 years. Corticosteroids were used by 
64.2 % of the patients in the treatment group and 
by 71.4 % in the control group. 
 
MTX nanoparticle characteristics 
 
Table 2: MTX nanoparticle characteristics 
 
Characteristic Value (mean ± 
SEM) 
Entrapment efficiency (%) 97.8 ± 4.2 
Particle size (nm) 164.4 ± 6.9 
Zeta potential (mV) -32.6 ± 3.7 
 
The MTX nanoparticle characteristics are shown 
in Table 2. Particle size is the most important 
characteristic of the nanoparticle formulation. 
The mean particle size was 164.4 nm, with PDI 
of 0.218. The low PDI indicated a uniform particle 
size distribution. The encapsulation efficacy was 
97.8 %. The zeta potential was -32.6 mV, 
indicating good stability of the formulation, which 
was attributable to a decrease in electrostatic 
repulsion between particles, which were 





The FTIR spectra of MTX and the MTX-alginate 
nanoparticles are shown in Fig. 1. Significant 
peaks were observed at 3391 cm-1 due to -NH 
stretching as well as the characteristic MTX 
peaks at 1644 and 1603 cm−1. In the spectrum of 
the MTX-alginate nanoparticle formulation, 
significant peaks were observed at 3437, 1644, 
and 1603 cm−1. Additional peaks were present 
due to the presence of polymer, indicating no 
interactions between the polymer and drug in this 
nanoparticle formulation. 
 
In-vitro drug release 
 
Fig. 2 shows the in vitro drug release of the MTX 
nanoparticles. The MTX nanoparticles showed 
an initial burst release of approximately 32.7 %, 
followed by a sustained release for up to 48 h. 
The early burst release may have been the result 
of drug precipitation from the nanoparticles or 
drug absorbed over the nanoparticles surface. 
The slow diffusion of the drug from the polymer 
matrix resulted in prolonged release. 
 
Treatment response  
 
The study included patients with moderate to 
severe disease. At baseline, the mean PCDAI 
and PUCAI scores were 48 (range, 33–59) and 
49.1 (range, 35–61), respectively. No significant 
differences were observed between groups. 
However, after 4, 8, and 12 weeks of treatment, 
the PCDAI (Fig. 3) and PUCAI (Fig. 4) scores 
were significantly different between groups. 
 
Table 1: Patient baseline characteristics according to group 
 
Characteristic Control group Treatment group 
No. of patients 14 14 
Male (female) 9 (5) 8 (6) 
Age, (years),  mean ± SEM (Range, 
years) 
12.7 ± 1.6 (9.1–16.8) 13.6 ± 1.4 (8.6–16) 
BMI ( range), 
kg/m2 
19.6 ± 1.5 (15.4–25.6) 18.2  ± 1.2 (14.4–
25.2) 











48.6 ± 2.2 
49.1 ± 2.3 
47.3 ± 1.9 
49.2 ± 1.7 
AST 37.4 ± 2.9 39.3 ± 2.3 
ALT 19.3 ± 1.7 15.7 ± 1.3 
CRP 3.8 ± 2.1 4.1 ± 1.7 
ESR 38.4 ± 2.3 41.3 ± 1.9 
BMI = Body Mass Index; CD = Crohn’s Disease; UC = Ulcerative Colitis; PCDAI = Paediatric Crohn’s Disease 
Activity Index; PUCAI = Paediatric Ulcerative Colitis Activity Index; AST = Aspartate transaminase; ALT = Alanine 
transaminase; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate] 
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                 Figure 2: Release profile of the MTX nanoparticles 
 
At 12 weeks, the mean PCDAI scores for the 
control and treatment groups were 22.3 ± 2.14 
and 16.8 ± 1.87, respectively (p = 0.022). 
Similarly, the mean PUCAI scores for the control 
and treatment groups were 24.3 ± 1.47 and 18.7 
± 1.92, respectively (p = 0.022). Table 3 shows 
the laboratory findings for the control and 
treatment groups according to treatment 
duration. The mean CRP and ESR values were 
significantly different between groups at 8 and 12 
weeks. At the beginning of the study, 9 patients 
in the treatment group and 10 in the control 
group were using steroids. However, the steroid 
dose decreased significantly in both groups, and 
12 patients (8 in MTX group and 5 in AZA group) 
were steroid free by the end of the study. After 
12 weeks of treatment, 13 of 28 patients 
achieved remission, 8 in the treatment group and 
5 in the control group. 
Toxicity 
 
The adverse events observed during the study 
are shown in Table 4. No deaths were reported 
in either group. The commonly reported adverse 
events were thrombocytopenia, leukopenia, 
nausea, and vomiting in the AZA group and 
thrombocytopenia, leukopenia, and liver enzyme 
elevation in the MTX group. No serious adverse 
events were reported in either group, with the 
exception of one patient in the AZA group, who 
developed grade 3 leukopenia, which resolved 
after discontinuation of the drug. No patients in 
the treatment group required discontinuation of 
the treatment. 
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Table 3: Laboratory findings in the treatment and control groups according to treatment duration 
 
Test 
Week 4 Week 8 Week 12 

































































24.3 ±  
1.37 0.1 
*P<0.05; ALT = Alanine transaminase; AST = Aspartate transaminase; CRP = C-reactive protein; ESR = 




         Figure 3: PCDAI Score of each group at different time intervals of study 
 
 
             Figure 4: PUCAI Score of each group at different time intervals of study 
 
Table 4: Adverse events reported in the study 
 
Adverse events Control group Treatment group 
Thrombocytopenia 4 1 
Leukopenia 2* 1 
Nausea 4 0 
Vomiting 5 0 
Elevated lever enzyme 0 2 
*One patient developed grade 3 leukopenia 
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Although several recent studies have 
investigated the effect of nanoparticle 
formulations in cell culture and small-animal 
models, particularly rodents, few have evaluated 
the effect of nanoparticle formulations in humans. 
Schmidt et al [16] were the first to use 
nanoparticles to treat patients with IBD. We 
evaluated the safety and efficacy of MTX 
nanoparticles administered to children with 
moderate to severe active IBD. We compared 
the performance of MTX nanoparticles against 
that of AZA. The baseline disease activity scores 
(PCDAI and PUCAI), ESR, CRP, and monthly 
steroid dose were similar between groups (p > 
0.05). 
 
A previous study found that a low dose of oral 
MTX administered weekly was a safe and 
effective steroid-sparing agent for patients with 
CD who did not respond to other therapies [8]. 
Based on this finding, we used a low dose of 
MTX in our study. Several controlled studies 
have investigated the effect of MTX in patients 
with IBD. In a double-blind, randomized, placebo-
controlled study of MTX in chronic active UC, 
Oren et al [17] found no advantage of MTX over 
placebo in patients with moderate to severe UC. 
By contrast, we found that the PUCAI scores 
following treatment with MTX nanoparticles were 
significantly lower than those in the control 
group. 
 
Ardizzone et al [18] found that MTX was effective 
in inducing remission in patients with chronic 
active CD; however, its efficacy was comparable 
to that of AZA [18]. By contrast, we found that 
MTX nanoparticles were significantly more 
effective than AZA. The greater effectiveness of 
the MTX nanoparticle may be due to the 
properties of nanoparticles. Several previous 
studies have shown that nanoparticle 
formulations have increased therapeutic efficacy 
and low toxicity compared with standard 
treatments, such as rolipram, 5-ASA, tacrolimus, 
and heparin [19]. Furthermore, nanoparticles 
help encapsulated drugs evade P-glycoprotein, 
the mucosal enzyme that metabolizes drugs, 
resulting in increased intracellular concentration 
of the drugs [20]. 
 
We found that the disease activity scores were 
significantly lower in the treatment than in the 
control group. A significant number of patients in 
both groups achieved remission; however, more 
patients in the MTX group achieved complete 
remission. Thus, our findings clearly indicate that 
MTX nanoparticles provide significant 
advantages over conventional AZA therapy. 
Moreover, we observed fewer and less severe 
adverse events than reported in previous MTX 
trials, and it was not necessary to discontinue 
treatment because of toxicity.  
 
Our favorable results may be due to the targeted 
and sustained drug delivery provided by the 
nanoparticle formulation. Schmidt et al. [16] 
reported that nanoparticles accumulated in the 
ulcerated lesions of patients with IBD. The 
increased efficacy and low toxicity observed in 
our study may be due to a similar accumulation 
effect. Moreover, several animal and cell culture 
studies have demonstrated preferential uptake of 
nanoparticles into inflamed tissue [[21]. Thus, it 
may be that the comparatively high efficacy and 
low toxicity of the MTX nanoparticle treatment 
observed in our study resulted from the capacity 
of the nanoparticles to shield the drug from 
systemic absorption and to be preferentially 
taken up and accumulate in the inflamed tissue. 
 
Limitations of the study 
 
The findings of this study was limited by the 
small sample size and the open-label nature of 
the design, which may be subject to bias. The 
random assignment of patients to the treatment 
and control groups reduced the likelihood of bias; 
however, further randomized double-blinded 




Several studies have shown that MTX is a good 
alternative in patients who cannot tolerate or are 
resistant to AZA/6MP treatment. Due to the high 
cost of immunosuppressant drugs, MTX should 
be considered before prior to drug therapy.  The 
occurrence of systemic adverse effects is the 
major limitation of MTX therapy; however, this 
limitation can be overcome by using a 
nanoparticle drug delivery system. The selective 
targeting of inflamed tissue underlies the 
increased efficacy and low toxicity of 
nanoparticle formulations compared with 
conventional therapy. Thus, MTX nanoparticles 
would be safer and more effective than the 
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